BillionToOne, Inc. (BLLN) witnessed a spectacular debut on the Nasdaq Global Select Market, with its stock soaring 66.67% in intraday trading. This impressive surge comes on the heels of the company's successful initial public offering (IPO), which was priced above the initial range and upsized due to strong investor demand.

The molecular diagnostics firm priced its IPO at $60 per share, raising approximately $273.1 million in gross proceeds. The offering, which was initially marketed at 3.85 million shares between $49 and $55 each, was upsized to nearly 4.6 million shares due to robust interest from investors. The strong debut reflects the market's enthusiasm for BillionToOne's innovative molecular diagnostic tests, including non-invasive prenatal screening and liquid biopsy for various diseases.

BillionToOne's impressive financial performance likely contributed to investor confidence. In the six months ended June 30, the company reported an 82% surge in revenue to $125.5 million, while narrowing its net loss to $4.2 million. As the stock continues to attract attention, investors will be closely watching the company's ability to capitalize on the growing molecular diagnostics market and deliver on its promising technology platform.